Animal Immune Technology Services-Tekbiotech-Yeast Display Service,Phage display technology

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Animal Immune Technology Services

Tek Biotech is committed to providing a full range of antibody discovery and optimization services. The company's core competence lies in the combination of Phage Display and Yeast Display technologies to achieve efficient antibody screening. In order to meet the application needs of antibody discovery and tumor target discovery of the majority of scientific research and pharmaceutical customers, Tek Biotech has more than 80 acres of alpaca and llama immunization bases, with alpacas originating from South America and other places, with a clear source of germplasm.

Alpaca immunization provides an ideal antibody source for nanoantibody generation. Through the company's nano-antibody discovery platform, Tek Biotech is able to continuously obtain high-quality immunogens and provide high-affinity and low-immunogenicity nano-antibody discovery services by combining our mature phage display technology and yeast display technology platforms.

In terms of phage display technology, Tek Biotech relies on the advanced Phagepro Tech&^#174 platform, wich is able to help customers screen antibodies with high specificity and high affinity through phage display libraries. Phage display is a powerful and flexible tool, especially suitable for antibody discovery and optimization, and has outstanding advantages in rapid discovery of novel antibody molecules for antibody drug discovery.

Meanwhile, yeast display technology is also one of the highlights of Tek Biotech’s technology. The Yeast Display Platform provides an efficient means of antibody screening and optimization by displaying antibody fragments on the surface of yeast cells. Compared with other systems, Yeast Display Technology has higher expression efficiency and antibody diversity, which is suitable for subsequent optimization work such as affinity maturation and antibody humanization.

To ensure the quality of service, Tek Biotech provides a one-stop solution from immunization, library construction to antibody screening. This includes immunization of alpaca/lama/american ostrich with client-specified antigens, collection and isolation of PBMCs, construction of nanoantibody demonstration libraries, as well as highly efficient panning and validation of the corresponding downstream activity by phage or yeast demonstration technologies. This comprehensive service can greatly shorten the antibody development cycle and improve the quality and diversity of antibodies to meet the diversified needs of customers in the development of antibody drugs and diagnostic reagents.

Fig. 1 animal immune antibody and PBMC isolation services

█ Animal Immunization Platform

Workflows	Times	Descriptions	Dates
Negative serum collection	Day 0	Pre-immunization serum collection 10mL	***
Primary immunization	Day 1	5ml pure virus intramuscular injection	***
Secondary immunization	Day 14	5ml pure virus intramuscular injection	***
Tertiary immunization	Day 28	5ml pure virus intramuscular injection	***
Triple immunization serum collection	Day 35	Collection of 2 ml of test serum for potency testing	***
Four times immunization	Day 42	5ml pure virus intramuscular injection	***
Tetraplex serum collection	Day 49	Collection of 2 ml of test serum for potency testing	***
Fifth immunization	Day 56	5ml pure virus intramuscular injection	***
Pentavalent serum collection	Day 63	Collection of 2 ml of test serum for potency testing	***
Neutralization potency test	Day 63	Simultaneous detection of serum neutralization potency of Tetraplex and Pentaplex sera	***

█ Quality Standards for Animal Immunization Platforms (QC Standards)

-- ELISA serum potency >10^5 against protein or virus antigens; ELISA serum potency >10^4 against peptide antigens (carrier protein coupled).

-- The number of immunizations 5-7 times

-- Isolated PBMC cells can be lysed in either lyophilized or Trizol lysed form to ensure that the 28S, 18S and 5S primary bands are clear.

-- For serum purification program, IgG purity >90%.

Animal Immune Technology Services Frequently Asked Questions

Q: After receiving immunity, animals have weaker immune responses, insufficient antibody production, or poor immune efficacy.

A: Consider increasing the immune dose, frequency, or duration, using appropriate immune adjuvants (such as Freund's adjuvant) to enhance the immune effect, and selecting more suitable immune animal strains.
Q: Animals exhibit non-specific reactions, leading to interference with experimental results.

A: Choose purer antigens, prepare more diluted antigen solutions, control experimental conditions, and reduce the occurrence of non-specific reactions.
Q: Animals experience excessive immune responses during the immune process, leading to tissue damage or immune related diseases.

A: Control the dosage and frequency of immunity to avoid excessive stimulation of the immune system; Choose appropriate immune animal strains and avoid susceptible animals.
Q: Animals exhibit immune suppression, leading to suppressed immune responses.

A: Consider using immunostimulants (such as polyclonal antibodies) to relieve immunosuppression, or adjusting treatment plans to avoid the influence of immunosuppressive factors.

Q: After receiving immunity, animals have weaker immune responses, insufficient antibody production, or poor immune efficacy.

A: Consider increasing the immune dose, frequency, or duration, using appropriate immune adjuvants (such as Freund's adjuvant) to enhance the immune effect, and selecting more suitable immune animal strains.
Q: Animals exhibit non-specific reactions, leading to interference with experimental results.

A: Choose purer antigens, prepare more diluted antigen solutions, control experimental conditions, and reduce the occurrence of non-specific reactions.
Q: Animals experience excessive immune responses during the immune process, leading to tissue damage or immune related diseases.

A: Control the dosage and frequency of immunity to avoid excessive stimulation of the immune system; Choose appropriate immune animal strains and avoid susceptible animals.
Q: Animals exhibit immune suppression, leading to suppressed immune responses.

A: Consider using immunostimulants (such as polyclonal antibodies) to relieve immunosuppression, or adjusting treatment plans to avoid the influence of immunosuppressive factors.

Consult Now Animal Immune Technology Services

Animal Immunization Technology Services

Recommended Services

Animal Immune Technology Services Frequently Asked Questions

Q: After receiving immunity, animals have weaker immune responses, insufficient antibody production, or poor immune efficacy.

Q: Animals exhibit non-specific reactions, leading to interference with experimental results.

Q: Animals experience excessive immune responses during the immune process, leading to tissue damage or immune related diseases.

Q: Animals exhibit immune suppression, leading to suppressed immune responses.

Q: After receiving immunity, animals have weaker immune responses, insufficient antibody production, or poor immune efficacy.

Q: Animals exhibit non-specific reactions, leading to interference with experimental results.

Q: Animals experience excessive immune responses during the immune process, leading to tissue damage or immune related diseases.

Q: Animals exhibit immune suppression, leading to suppressed immune responses.

Consult Now Animal Immune Technology Services